SOX17 Antibody (614013) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB19241H
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry, Intracellular Staining by Flow Cytometry
Label
HRP
Antibody Source
Monoclonal Mouse IgG1 Clone # 614013
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant human SOX17
Asp177-Val414
Accession # Q9H6I2
Asp177-Val414
Accession # Q9H6I2
Specificity
Detects human SOX17 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for SOX17 Antibody (614013) [HRP]
Application
Recommended Usage
Immunocytochemistry
Optimal dilutions of this antibody should be experimentally determined.
Intracellular Staining by Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SOX17
Long Name
Transcription Factor SOX17
Alternate Names
FLJ22252, SRY (sex determining region Y)-box 17, SRY-related HMG-box transcription factor SOX17, transcription factor SOX-17, VUR3
Gene Symbol
SOX17
Additional SOX17 Products
Product Documents for SOX17 Antibody (614013) [HRP]
Product Specific Notices for SOX17 Antibody (614013) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...